The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression
Abstract
Modafinil is a wake-promoting agent approved by the Federal Drug Administration for the treatment of narcolepsy. Preliminary evidence indicates that modafinil may improve fatigue and excessive sleepiness associated with a variety of conditions. The purpose of this study was to investigate the utility of modafinil as an adjunctive treatment of depressed patients. Subjects with a history of major depression with partial response on a stable therapeutic dose of an antidepressant were eligible to participate. All subjects endorsed complaints of significant fatigue and/or excessive sleepiness on clinical assessment. Modafinil was added to their existing regimen at a dose of 100 to 400 mg/d for 4 weeks. Subjects were assessed at 2-week intervals for improvement using the standard depression scales (HDRS, BDI, CGI), fatigue scales (VASF, FSI), and a neuropsychologic battery. Thirty-five subjects were entered and 31 subjects completed the 4-week trial. Significant improvements were seen across all 3 measures of depression (HDRS, BDI, CGIS) and both measures of fatigue (VASF, FSI). On the neurocognitive battery, significant gains in the Stroop Interference Test were seen at 4 weeks, whereas the other cognitive tests showed no change. Modafinil may be a useful and a well-tolerated adjunctive agent to standard antidepressants in the treatment of major depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and increase feature-based selective attention and clinical symptoms in depressed patients119.”
From Paying attention to attention in depression (2019) · cites this paper as [119]
In the citing paper
“Modafinil has only been tested as a procognitive agent for MDD in a 4-week open-label trial, enrolling 35 patients with MDD with a partial response to an antidepressant at a stable dose [147].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [147]
In the citing paper
“However, neurocognitive function was not a primary outcome of this small, uncontrolled trial.”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [147]
Citations
Cites
Rammohan, K. W. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.2.179 · Cited by 441
Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy
Fry (1998) · Annals of Neurology · doi:10.1002/ana.410430115 · Cited by 398
Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy
US Modafinil in Narcolepsy Multicenter Study Group (2000) · Neurology · doi:10.1212/wnl.54.5.1166 · Cited by 363
Modafinil as Adjunct Therapy for Daytime Sleepiness in Obstructive Sleep Apnea
PACK, A. I., BLACK, J. E., SCHWARTZ, J. R. L., & MATHESON, J. K. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2103032 · Cited by 324
Broughton, R., Fleming, J. A. E., George, C. F., Hill, J. D., Kryger, M. H., Moldofsky, H., Montplaisir, J. Y., Morehouse, R. L., Moscovitch, A., & Murphy, W. F. (1997) · Neurology · doi:10.1212/wnl.49.2.444 · Cited by 285
Naps and modafinil as countermeasures for the effects of sleep deprivation on cognitive performance.
Batéjat, D., & Lagarde, D. (1999) · PubMed · Cited by 234
Tylee, A. T., Gastpar, M., Lépine, J., & MENDLEWICZ, J. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199905002-00001 · Cited by 221
Modafinil Augmentation of Antidepressant Treatment in Depression
Menza, M. A., Kaufman, K. R., & Castellanos, A. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0510 · Cited by 200
TAYLOR, F. B., & Russo, J. E. (2000) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2000.10.311 · Cited by 182
A Potential Clinical Use for Methylphenidate with Tricyclic Antidepressants
Wharton, R. N., Perel, J. M., Dayton, P. G., & Malitz, S. (1971) · American Journal of Psychiatry · doi:10.1176/ajp.127.12.1619 · Cited by 134
Research works printed but not linked: 1
- 1998, US Modafinil in Narcolepsy Multicenter Study Group., Ann Neurol, 43, 88
Cited by
Sorted by citations
Items 101–145 of 145
Pharmacokinetics and tolerability of modafinil tablets in Chinese subjects
Xu, P., Li, H.-D., Zhang, B., Xiao, Y.-W., Yuan, H., & Zhu, Y. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00934.x · Cited by 9
“Short-term clinical studies have shown improved wakefulness in patients with other conditions such as multiple sclerosis (7, 8), major depression(9, 10), cancer-related fatigue (11) and Parkinson’s disease (12, 13).”
BackgroundUpdate on augmentation of antidepressant response in resistant depression
DeBattista, C., & Lembke, A. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0064-x · Cited by 9
“For example, our group [ 12 ] showed that 31 partial responders to antidepressants who were treated with 100 to 400 mg per day of modafinil showed significant improvement in fatigue, depression, and cognition.”
MethodSelf-citationEffect of armodafinil on cognition in patients with HIV/AIDS and fatigue
McElhiney, M. C., Rabkin, J. G., van Gorp, W. G., & Rabkin, R. (2013) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2013.823910 · Cited by 8
Immediate Switching From Moclobemide to Duloxetine May Induce Serotonin Syndrome
Jiménez‐Genchi, A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1122f · Cited by 8
Solubility Measurements and Correlation of Modafinil in Neat Solvents and Binary Solvent Mixtures
Mbodji, A., Agrawal, S. G., Cruz, K. M., Perez-Molares, D., Vlaar, C. P., Duconge-Soler, J., Monbaliu, J. M., & Stelzer, T. (2024) · Journal of Chemical & Engineering Data · doi:10.1021/acs.jced.3c00738 · Cited by 7
Iravani, S., Cai, L., Ha, L., Zhou, S., Shi, C., Ma, Y., Yao, Q., Xu, K., & Zhao, B. (2020) · Medicine · doi:10.1097/md.0000000000019197 · Cited by 7
“In addition, combining stimulants ormodafinil with these first-line treatments may provide a better effect in improving fatigue symptoms.([20]) However, at present no current Food and Drug Administration-approved treatments are available for fatigue.”
BackgroundDepression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Modafinil as an Alternative to Methylphenidate as Augmentation for Depression Treatment
Xiong, G. L., Christopher, E. J., Goebel, J. A., & Durham, N. C. (2005) · Psychosomatics · doi:10.1176/appi.psy.46.6.578 · Cited by 6
Excessive daytime sleepiness in psychiatry: A relevant focus for clinical attention and treatment?
Hawley, C. J. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600578904 · Cited by 5
“[59] De Battista C, Lembke A, Solvason HB, Poirier J.”
Residual hypersomnia in unipolar and bipolar depression: A systematic review
Kwaśna, J., Kwaśny, A., Wilkowska, A., Bychowski, M., & Cubała, W. J. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2429429 · Cited by 6
“…for managing excessive sleepiness in individuals with narcolepsy, obstructive sleep apnoea, and shift work sleep disorder, modafinil shows potential efficacy in alleviating residual hypersomnia, as suggested by some studies (Menza et al. 2000; DeBattista et al. 2003; 2004; Fava et al. 2006).”
(2005) · CRC Press eBooks · doi:10.1201/b14455-5 · Cited by 5
Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders
Venero, C. (2015) · Cognitive Enhancement · doi:10.1016/b978-0-12-417042-1.00010-3 · Cited by 4
The Failure of Evidence-Based Medicine to Guide Treatment of Antidepressant Nonresponders
Thase, M. E. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1202 · Cited by 4
The role of eugeroics in the treatment of affective disorders
Urban, A. E., & Cubała, W. J. (2018) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/90687 · Cited by 4
“There was no negative impact of modafinil on cognition [13].”
BackgroundDrappatz, J., & Wen, P. Y. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-166-0_4 · Cited by 3
Sonolência excessiva diurna e depressão: causas, implicações clínicas e manejo terapêutico
Chellappa, S. L. (2009) · Revista de Psiquiatria do Rio Grande do Sul · doi:10.1590/s0101-81082009000400001 · Cited by 6
Depression: An Update for the Clinician
Nierenberg, A. A., Eidelman, P., Wu, Y. P., & Joseph, M. (2005) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.3.1.3 · Cited by 3
Depression and sleepiness: a chronobiological approach
Chellappa, S. L., & Cajochen, C. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511762697.027 · Cited by 3
Combining Medications to Achieve Remission
Zajecka, J., & Goldstein, C. (2009) · doi:10.3109/9781420084887-5 · Cited by 3
Evidence-based pharmacotherapy of major depressive disorder
Dupuy, J. M., Ostacher, M. J., Huffman, J. C., Perlis, R. H., & Nierenberg, A. A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.005 · Cited by 3
Modafinil for Promoting Wakefulness in Critically Ill Patients: Current Evidence and Perspectives
Kakavas, S., & Karayiannis, D. (2025) · Clocks & Sleep · doi:10.3390/clockssleep7040062 · Cited by 2
“Modafinil has been shown to alleviate EDS and fatigue in patients with amyotrophic lateral sclerosis [36], multiple sclerosis [37], cancer-related or opioid-induced fatigue [38,39], and major depressive disorder [40,41].”
Pharmacological treatment approaches to difficult-to-treat depression
Chan, H., Mitchell, P. B., Loo, C. K. A., & Harvey, S. B. (2012) · The Medical Journal of Australia · doi:10.5694/mjao12.10495 · Cited by 2
Mood and Anxiety in Cancer Pain
Key, R. G., & BREITBART, W. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-99684-4_51 · Cited by 1
Combining Medications to Achieve Remission
Zajecka, J., & Goldstein, C. (2009) · Medical psychiatry · doi:10.3109/9781420084887.003 · Cited by 1
Chapter 9. Augmentation Strategies for Treatment-Resistant Disorders
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd09 · Cited by 1
Modafinil in the treatment of selected mental disorders
Dyrda, W., Smułek, D., Wichniak, A., & III Klinika Psychiatryczna i Ośrodek Medycyny Snu, I. P. I. N. W. W. (2021) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2021.0022
Augmentation Strategies for Treatment-Resistant Disorders
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as09 · Cited by 1
Staub, F. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544880.031 · Cited by 1
BREITBART, W. S., Lichtenthal, W. G., Pessin, H., & LEE, G. C. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511642357.026 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Boosting impulse control in addiction. Pharmacological neuroimaging studies
Schmaal, L. (2013) · UvA-DARE (University of Amsterdam)
Kutcher, M. (2004) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.9.4.6.48744
Depresif Bozukluklarin Tedavisinde Psikostimulanlar in the Treatment of Depressive Disorders
Ekinci, O., & Bolek, S. (2015)
Pharmacological Approaches to Treatment-Resistant Depression
D, M. F. M., & Nierenberg, A. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50046-9
Ryan, A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5164-8_14
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as03 · Cited by 1
Augmentation Strategies for Treatment-Resistant Disorders
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as09
Current awareness in human psychopharmacology
(2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.567
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as03
Pavel, A. N., Dutu, I., Giurgiuca, A., & Matei, V. P. (2019) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2019.3.2
The Management of Neurocognitive Impairment in Mood Disorders
Gallagher, P., & Young, A. H. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.023
Griffiths, C., Banazadeh, A., & Mu, M. (2025) · Open Journal of Depression · doi:10.4236/ojd.2026.151001
Cognitive Dysfunction and Suicide
Sunzeri, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_19
(2007) · PubMed · Cited by 453
Metadata
- Authors
- DeBattista, C., Lembke, A., Solvason, H. B., Ghebremichael, R., & Poirier, J.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- DeBattista, Charles
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2004-02
- Volume
- 24
- Issue
- 1
- Pages
- 87-90
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1986635669
- Cited by
- 144
- References
- 24
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 5 · 2019: 8 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 6 · 2014: 4 · 2013: 7 · 2012: 3
- FWCI
- 12.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- modafinil, major depressive disorder, adjunctive therapy, fatigue, excessive sleepiness, wakefulness-promoting agents, antidepressant response, cognitive function, Stroop interference, neuropsychological assessment
- MeSH terms
- Modafinil, Adult, Aged, Antidepressive Agents, Benzhydryl Compounds, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Drug Tolerance, Fatigue, Female, Humans, Disorders of Excessive Somnolence, Male, Middle Aged, Prospective Studies, Psychiatric Status Rating Scales, Time Factors, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
